Education
About Us
Working with TipRanks
Follow Us
Prenetics Group Limited (PRE)
:PRE
Top Page
Prenetics Group
(NASDAQ:PRE)
44Neutral
Prenetics Group (PRE) vs. S&P 500 (SPY)
Market Cap
$46.55M
Dividend YieldN/A
Average Volume (3M)5.97K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth-68.28%
EPS Growth0.07%
CountryUS
Employees320
SectorHealthcare
Sector Strength64
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-3.99
Shares Outstanding10,636,254
10 Day Avg. Volume10,490
30 Day Avg. Volume5,968
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.95
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$13.00Price Target Upside236.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Prenetics Group Business Overview & Revenue Model
Company DescriptionPrenetics Group (PRE) is a leading genomics and precision oncology company. The company operates in the healthcare and biotechnology sectors, offering a range of products and services that include genetic testing, personalized health management solutions, and advanced cancer screening technologies. Its core mission is to provide accessible and actionable health insights to empower individuals and healthcare providers in making informed decisions.
How the Company Makes MoneyPrenetics Group makes money through a diversified revenue model centered around its genetic testing and diagnostic services. The company generates revenue by selling its genetic testing kits directly to consumers and through partnerships with healthcare providers and corporate clients. Additionally, Prenetics has established significant partnerships with hospitals and clinics to offer its precision oncology solutions as part of their patient care services. The company also earns income by licensing its technology and intellectual property to third parties, expanding its reach and application in the healthcare industry. Key factors contributing to its earnings include strategic collaborations with leading healthcare institutions and continuous innovation in its testing and diagnostic capabilities.
Prenetics Group Financial Statement Overview
Summary
Prenetics Group is facing significant financial challenges, with declining revenues, negative profitability, and cash flow issues. The balance sheet shows some strength with low leverage, but overall financial performance is weak and needs improvement.Income Statement
Prenetics Group has faced significant challenges with declining revenues and negative profit margins. The net profit margin and EBIT margin are negative, indicating substantial losses. Revenue has decreased sharply from 2022 to 2023, showing a significant decline in business performance. The company needs to reverse these trends to improve its financial health.25
Negative
Balance Sheet
Prenetics Group's balance sheet shows some strengths, such as relatively low debt levels resulting in a low debt-to-equity ratio. However, the company's return on equity is negative due to ongoing losses. The equity ratio is strong, indicating a solid capital structure with high equity relative to total assets.55
Neutral
Cash Flow
The cash flow situation is concerning, with negative operating cash flow and free cash flow in 2023. The free cash flow to net income ratio is negative, reflecting cash outflows amid losses. However, the company has maintained a strong cash position, which may provide some flexibility to manage operations.30
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 22.65M | 21.74M | 275.76M | 275.85M | 65.18M | 9.23M |
| Gross Profit | |||||
| 11.84M | 8.83M | 131.55M | 106.13M | 26.34M | 2.72M |
| EBIT | |||||
| -46.38M | -51.91M | 207.42M | -10.35M | 967.46K | -18.23M |
| EBITDA | |||||
| -40.43M | -47.90M | -214.28M | -157.70M | -1.42M | -18.57M |
| Net Income Common Stockholders | |||||
| -51.91M | -62.72M | -190.45M | -174.02M | -1.96M | -20.20M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 72.74M | 72.74M | 164.20M | 45.19M | 14.49M | 11.82M |
| Total Assets | |||||
| 254.17M | 254.17M | 307.98M | 148.51M | 78.88M | 29.69M |
| Total Debt | |||||
| 2.37M | 2.37M | 6.65M | 5.27M | 1.67M | 899.55K |
| Net Debt | |||||
| -43.34M | -43.34M | -140.01M | -30.02M | -12.82M | -10.62M |
| Total Liabilities | |||||
| 44.01M | 44.01M | 67.94M | 549.40M | 47.88M | 12.83M |
| Stockholders Equity | |||||
| 206.36M | 206.36M | 237.06M | -400.81M | 31.08M | 16.91M |
| Cash Flow | Free Cash Flow | ||||
| 3.77M | -14.68M | 8.17M | 2.00M | -5.94M | -2.26M |
| Operating Cash Flow | |||||
| 3.77M | -13.76M | 14.51M | 13.42M | -2.88M | -1.88M |
| Investing Cash Flow | |||||
| 0.00 | -82.95M | -46.14M | -22.02M | -5.97M | -4.60M |
| Financing Cash Flow | |||||
| 0.00 | -4.70M | 143.32M | 29.32M | 11.84M | -569.14K |
Prenetics Group Technical Analysis
Negative
3.86
Price Trends
5.02
Negative
5.04
Negative
5.12
Negative
Market Momentum
-0.32
Positive
23.89
Positive
29.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRE, the sentiment is Negative. The current price of 3.86 is below the 20-day moving average (MA) of 4.42, below the 50-day MA of 5.02, and below the 200-day MA of 5.12, indicating a bearish trend. The MACD of -0.32 indicates Positive momentum. The RSI at 23.89 is Positive, neither overbought nor oversold. The STOCH value of 29.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRE.
Prenetics Group Risk Analysis
Prenetics Group disclosed 58 risk factors in its most recent earnings report. Prenetics Group reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Prenetics Group Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $8.34B | ― | -37.09% | ― | 10.37% | -389.98% | |
53 Neutral | $5.66B | ― | -4584.47% | ― | 31.04% | 16.91% | |
52 Neutral | $1.28B | ― | -8.54% | ― | 11.65% | 11.33% | |
51 Neutral | $841.87M | ― | -17.15% | ― | 12.15% | 61.33% | |
49 Neutral | $6.86B | 0.72 | -52.93% | 2.49% | 20.83% | 1.11% | |
46 Neutral | $2.36B | ― | -50.74% | ― | -7.03% | -20233.78% | |
44 Neutral | $46.55M | ― | -23.82% | ― | -68.28% | 0.07% |
* Healthcare Sector Average
Performance Comparison
PRE
Prenetics Group
3.81
-0.24
-5.93%
EXAS
Exact Sciences
44.99
-24.07
-34.85%
MYGN
Myriad Genetics
9.22
-12.10
-56.75%
QDEL
QuidelOrtho
35.87
-12.07
-25.18%
NEO
NeoGenomics
9.48
-6.24
-39.69%
GH
Guardant Health
45.15
24.52
118.86%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.